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Eﬃcient 2-step biocatalytic strategies for the
synthesis of all nor(pseudo)ephedrine isomers†
Torsten Sehl,a Helen C. Hailes,b John M. Ward,c Ulf Menyes,d Martina Pohla and
Dörte Rother*a
Chiral 1,2-amino alcohols are important building blocks for chemistry and pharmacy. Here, we developed
two diﬀerent biocatalytic 2-step cascades for the synthesis of all four nor(pseudo)ephedrine (N(P)E)
stereoisomers. In the ﬁrst one, the combination of an (R)-selective thiamine diphosphate (ThDP)-depen-
dent carboligase with an (S)- or (R)-selective ω-transaminase resulted in the formation of (1R,2S)-NE or
(1R,2R)-NPE in excellent optical purities (ee >99% and de >98%). For the synthesis of (1R,2R)-NPE, space–
time yields up to ∼26 g L−1 d−1 have been achieved. Since a highly (S)-selective carboligase is currently
not available for this reaction, another strategy was followed to complement the nor(pseudo)ephedrine
platform. Here, the combination of an (S)-selective transaminase with an (S)-selective alcohol dehydro-
genase yielded (1S,2S)-NPE with an ee >98% and a de >99%. Although lyophilized whole cells are cheap
to prepare and were shown to be appropriate for use as biocatalysts, higher optical purities were observed
with puriﬁed enzymes. These synthetic enzyme cascade reactions render the N(P)E-products accessible
from inexpensive, achiral starting materials in only two reaction steps and without the isolation of the
reaction intermediates.
Introduction
Norpseudoephedrine (NPE) and norephedrine (NE) belong to
the amphetamine family of ephedra alkaloids and can be
found in plants like Khat (Catha edulis)1,2 and in some
Ephedra species.3 In the human body they are known to have a
sympathomimetic function4 and act as non-selective adrener-
gic receptor agonists and norepinephrine re-uptake
inhibitors.5 As pharmaceuticals, they have been used to induce
mydriasis (dilation of pupils), to stabilize blood pressure, as
nasal decongestants, appetite suppressants, and in cold/flu
medication.6–9 In most countries N(P)Es are available only on
prescription.10 On the German market, cathine ((1S,2S)-NPE)
is currently sold for its appetite suppressant function as an
active ingredient in ALVALIN®.11,12 In addition to their
pharmacological interest, the four N(P)Es stereoisomers are
valuable synthons, ligands, and chiral auxiliaries in organic
syntheses.13,14 Indeed, a SciFinder® search revealed that N(P)Es
have been used as reactants in >5000 diﬀerent reactions.15
So far, >350 diﬀerent synthetic strategies towards N(P)E
stereoisomers have been described in SciFinder®.15 Still,
methods for the asymmetric synthesis of nor(pseudo)ephe-
drines from inexpensive starting materials are rare and require
multi-step preparative routes, are based on relatively expensive
reagents or lack high enantio- and diastereomeric selectiv-
ities.16 Single enzymatic steps17–20 and enzyme cascades21–25
have significant potential in chiral asymmetric synthesis. If a
suitable multi-step cascade is performed in one pot, it can be
a highly selective, step- and atom-eﬃcient strategy which
circumvents a time consuming and expensive isolation of
intermediates.26,27
For the synthesis of (1R,2R)-norpseudoephedrine and
(1S,2R)-norephedrine, we recently described a 1-pot 2-step
enzyme cascade with overall conversions of up to >95%. The
combination of a highly (R)-selective carboligase with either an
(S)- or (R)-selective ω-transaminase (TA) gave access to these
products in high optical purities of ee >99% and de >98%.28
However, synthesis of the two remaining stereoisomers
(1S,2S)-NPE and (1S,2R)-NE requires a highly (S)-selective thia-
mine diphosphate (ThDP)-dependent carboligase in the first
reaction step (Scheme 1A), which is currently not available
among known wild-type enzymes. Due to our knowledge of the
reaction mechanism and factors influencing chemo- and
stereoselectivities of ThDP-dependent enzymes, a variant has
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been designed of the pyruvate decarboxylase from Acetobacter
pasteurianus, producing phenylacetylcarbinol (PAC) (S)-selec-
tively for the first time.29
Here, we describe the evaluation of this enzyme for the ana-
logous 1-pot 2-step synthesis of (1S,2R)-NE and (1S,2S)-NPE. To
avoid a chiral purification step of the resulting nor(pseudo)-
ephedrine diastereomers, an alternative synthetic strategy
(‘TA-ADH’, Scheme 1B) was investigated. Starting from 1-phenyl-
propane-1,2-dione (1,2-PPDO), in principle all four N(P)E
isomers should be accessible in two steps by combining
respective stereoselective ω-TAs in the first with alcohol dehy-
drogenases (ADHs) in the second cascade step. We discuss
here advantages and bottlenecks of both strategies.
Synthesis strategy A: carboligase-TA
A-1: (1R,2R)-NPE – high space–time-yields using benzaldehyde
emulsions
To date, the biocatalytic 2-step synthesis of (1R,2R)NPE
(Scheme 2) was only performed in aqueous buﬀer with low
substrate concentrations (maximum of 20 mM benzaldehyde)
with space–time-yields (STY) of ∼2 g L−1 d−1.28 To increase the
productivity of this cascade, the enzyme concentration was
optimized and its performance in the presence of higher benz-
aldehyde concentrations was investigated (up to 100 mM
benzaldehyde).
The 2-step cascade, a combination of the AHAS-I from
E. coli and the (R)-selective TA from Aspergillus terreus (At-(R)-
TA) for the synthesis of (1R,2R)-NPE, could be performed in
one pot.28 Starting from equimolar concentrations of pyruvate
and benzaldehyde (10 mM each) in the carboligation step, the
reductive amination could be performed in an optimized
manner with a 5-fold excess of D-alanine as the co-substrate.
This one pot approach is feasible without addition of further
compounds or enzymes, despite the low equilibrium constant
of the reductive amination (Keq = 2.31 × 10
−3), because AHAS-I
removes the co-product pyruvate by converting it to acetolac-
tate and thus shifts the equilibrium to the product side.28
Although the cascade could be performed in a simultaneous
mode (both enzymes added simultaneously), the sequential
mode (TA added after the AHAS-I reaction was completed)
proved to be advantageous due to a lower by-product for-
mation (benzylamine, formed by reductive amination of benz-
aldehyde).28 In order to further optimize the biocatalytic
approach, the minimum amount of enzymes required for a
reaction containing 20 mM benzaldehyde, 20 mM pyruvate,
and 100 mM D-alanine (see Fig. 1) was determined.
It was found that 0.5 mg mL−1 AHAS-I and 0.4 mg mL−1
At-(R)TA were suﬃcient to achieve 95% conversion of 20 mM
Scheme 1 Two 1-pot 2-step strategies for the synthesis of nor(pseudo)-
ephedrines combining (A) carboligases and transaminases (TAs) and (B)
TAs and alcohol dehydrogenases (ADHs).
Fig. 1 Reaction optimization for the 1-pot 2-step sequential cascade of
(1R,2R)-NPE with diﬀerent concentrations of AHAS-I and At-(R)TA. Reac-
tion parameters: 20 mM benzaldehyde, 20 mM pyruvate and 100 mM
D-alanine in 100 mM HEPES (pH 7.5 with 200 µM PLP, 50 µM FAD,
100 µM ThDP, 5 mM MgCl2). Without isolation of the reaction intermediate
(R)-PAC, lyophilized At-(R)TA was added 90 min after the addition of
AHAS-I (in the given concentrations (pink dots)). The complete reaction
was analyzed after another 12 h.
Scheme 2 Strategy A-1: combination of the (R)-selective AHAS-I from
E. coli and (R)-selective transaminase from A. terreus (At-(R)TA) for the
synthesis of (1R,2R)-NPE.
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benzaldehyde within 13.5 h (Fig. 1). This corresponds to a
space–time yield of ∼5 g L−1 d−1 over both reaction steps.
To enhance the reaction eﬃciency further, the initial benz-
aldehyde (BA) and pyruvate concentration was increased to 25,
50, 75 and 100 mM but using a constant 5-fold excess of
alanine. In line with the optimized reaction parameters, per
mmol benzaldehyde 0.025 mg mL−1 AHAS-I (90 min reaction
time) and 0.02 mg mL−1 At-(R)TA (12 h reaction time) were
added.
Although benzaldehyde is not soluble in aqueous buﬀer
>50 mM, in all cases conversions of up to 90% were observed
with less than 5% benzylamine by-product formation (Fig. 2).
Interestingly, this emulsion system did not significantly influ-
ence the reaction performance. In line with these data, finally
space–time-yields up to 26 g L−1 d−1 (1R,2R)-NPE were achieved
starting from 100 mM benzaldehyde and 90% conversion
could be observed within 13.5 h.
A-2: (1R,2S)-NE – application of lyophilized whole cells
The use of whole cells can reduce the catalyst cost by a factor
of 10 and is particularly advantageous if side reactions do not
occur.30 For an economically feasible large scale application,
access to (1R,2S)-NE has been demonstrated by a combination
of AHAS-I and Cv-(S)TA (Scheme 3).28 Here, the use of enzymes
as lyophilized whole cells without enzyme purification was
investigated, which features the benefit of easy handling
compared to wet cells (e.g. in terms of weighing out small
quantities).
Concerning the first step, purified AHAS-I shows a high
initial rate activity of ∼1.8 U mgprotein−1 for the catalyzed carbo-
ligation of benzaldehyde and (decarboxylated) pyruvate, which
is within the range of industrially suitable catalysts17 (Fig. 3A).
The use of 5 mg mL−1 of lyophilized recombinant E. coli whole
cells (LWC) yielded a similar reaction velocity under equivalent
reaction conditions (Fig. 3B), which is a consequence of the
lower protein amount per mgcatalyst (for comparison of AHAS-I
concentrations see SDS-PAGE in ESI Fig. 1†). In both cases a
complete conversion of 10 mM benzaldehyde was achieved
within ∼0.5 h. This corresponds to a STY of ∼72 g L−1 d−1 and
Scheme 3 Synthetic strategy A-2: combination of the (R)-selective
AHAS-I and the (S)-selective transaminase Cv-(S)TA gives access to
(1R,2S)-NE.
Fig. 3 Carboligation of 10 mM benzaldehyde and 10 mM pyruvate
catalyzed either by 0.5 mg mL−1 puriﬁed AHAS-I (A) or 5 mg mL−1 lyo-
philized whole cells (B). Each reaction was performed in 100 mM HEPES
(pH 7.5, 50 µM FAD, 100 µM ThDP, 5 mM MgCl2) at 25 °C.
Fig. 2 1-Pot 2-step sequential cascade for the synthesis of (1R,2R)-NPE
with 25, 50, 75 or 100 mM benzaldehyde (BA) and equimolar concen-
trations of pyruvate (Pyr). 0.025 mg mL−1 AHAS-I were used per mM
benzaldehyde. After 90 min reaction time, 0.02 mg mL−1 At-(R)TA and
2.5 mM D-alanine were added per mM initial benzaldehyde concen-
tration. The solution was extracted after a further 12 h reaction time.
Reaction parameter: 100 mM HEPES pH 7.5, 200 µM PLP, 50 µM FAD,
100 µM ThDP, 5 mM MgCl2, 25 °C.
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a specific STY (STY gcatalyst
−1) for LWC of ∼14 g L−1 d−1 gLWC−1
and for a purified enzyme of ∼144 g L−1 d−1 genzyme−1.
Additionally, a comparison of LWC and purified enzymes
for the second reductive amination step of (R)-PAC using the
Cv-(S)TA was investigated. In a first trial with L-alanine as an
amine donor no NPE product formation was observed (data
not shown). However, exchange of L-alanine by (S)-α-methyl-
benzylamine ((S)-α-MBA) in a reaction containing 10 mM
(R)-PAC and 5 mg mL−1 LWC resulted in a conversion of 85%
(see Fig. 4). Notably, we observed a lag phase of 60 min before
product formation started when the reductive amination step
was catalyzed with lyophilized whole cells (Fig. 4). This lag
phase seems to be caused by membrane required rehydration
time of the lyophilized whole cells in the aqueous buﬀer and
could be reduced by a pre-incubation of the LWC in reaction
buﬀer (see ESI chapter 3.1.4†). Still, the reaction rate with
5 mg mL−1 LWC was almost as fast as with 1 mg mL−1 purified
enzyme. In both cases a conversion of ∼85% was reached
within 3 h, which corresponds to a STY of ∼10 g L−1 d−1.
According to this, the calculated specific STY for LWC is ∼2 g
L−1 d−1 gLWC
−1 and for purified enzyme ∼10 g L−1 d−1
genzyme
−1.
The application of lyophilized whole cells, in general, was
found to be suitable for the “carboligase-TA” cascade. This is
of special interest for a reaction process, since overall process
costs are reduced when enzyme purification can be avoided.
Compared to a similar reaction with lyophilized enzymes, the
catalyst cost can be significantly lowered by a factor of 10, as
was suggested by a general estimation of the catalyst cost by
Tufvesson and co-workers.30
A-3, A-4: access to (1S,2R)-NE and (1S,2S)-NPE
The most promising enzyme for (S)-selective carboligation
of benzaldehyde and acetaldehyde is ApPDC-E469G.29,31
Although the stereoselectivity for (S)-PAC of 89% ee is
not optimal, the 2-step cascade in combination either
with an (S)- or (R)-selective ω-TA would result in the
formation of (1S,2S)-NPE (Scheme 4; A-3) or (1S,2R)-NE
(Scheme 4; A-4) if (S)-PAC is accepted as substrate.
The carboligation step catalyzed by ApPDC-E469G resulted
in a final conversion of 95% within 48 h (40 mM benz-
aldehyde, 400 mM pyruvate, 2.5 mM MgSO4, 100 µM ThDP,
50 mM potassium phosphate, pH 7).32 Under these reaction
conditions, the obtained (S)-PAC had an ee of only ∼70%. Its
following reductive amination using 10 mM isolated (S)-PAC
with 15 mM (R)- or (S)-α-MBA, respectively, and (R)-selective At-
(R)TA resulted in the formation of predominantly (1S,2R)-NE
with >95% conversion. With the (S)-selective Cv-(S)TA, (1S,2S)-
NPE was produced with similar conversions >95%. As
expected, both products had a high enantiomeric purity of
>99%, but only a low diastereomeric excess of ∼70%. These
results highlight that both PAC enantiomers are accepted by
both ω-TAs and are further reduced with high stereoselectivity.
The missing influence of the chiral vicinal hydroxyl group on
the TA reactivity is in line with data for a similar substrate
(1,3-dihydroxy-1-phenylpropane-2-one) published earlier.33 To
further increase the optical purities of the N(P)E in our syn-
thetic cascade approach, a catalyst with higher stereoselectivity
for the (S)-PAC synthesis would be required. Since so far
further rational design attempts have been unsuccessful, the
combination of ω-TA with oxidoreductases (synthesis strategy
B) was subsequently investigated to access these two products
in higher optical purities.
Synthesis strategy B: TA–ADH
A novel reaction cascade consisting of a TA in the first step
and an ADH in the second step could circumvent the low
optical purity in the “carboligase-TA” cascade for the synthesis
of (1S,2R)-NE and (1S,2S)-NPE. Using 1-phenylpropane-1,2-
dione (1,2-PPDO) as a substrate, the combination of an (S)-
selective TA (here Cv-(S)TA) either with the (R)-selective ADH
from Ralstonia sp. (RADH) or the (S)-selective ADH from Lacto-
bacillus brevis (LbADH) could give access to (1R,2S)-NE and
Fig. 4 Cv-(S)TA catalyzed reductive amination of 10 mM (R)-PAC in
the presence of 10 mM (S)-α-MBA catalyzed by either puriﬁed enzyme
(1 mg mL−1) or lyophilized cells (5 mg mL−1).
Scheme 4 Synthesis strategy A-3, A-4: combination of the (S)-selective
carboligase ApPDC-E469G with either the (S)-selective TA Cv-(S)TA
(A-3) or the (R)-selective TA At-(R)TA (A-4) gives access to (1S,2S)-NPE
(A-3) or (1S,2R)-NE (A-4), respectively.
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(1S,2S)-NPE (strategy B-1; Scheme 5). Since the enzymes for
both steps are highly selective for aryl-aliphatic substrates, as
was earlier demonstrated for oxidoreductases34 and ω-TAs28
the products should be accessible in high optical purity. To
complete the strategies towards all possible stereoisomers of
N(P)E with high stereoselectivities, the access to (1S,2R)-NE
and (1R,2R)-NPE was investigated by a combination of the
(R)-selective At-(R)TA with LbADH and RADH, respectively
(strategy B-2; Scheme 5). Finally, the application of diﬀerent
enzyme preparations (lyophilized whole cells, purified
enzymes or crude cell extract) was compared.
In order to determine optimal reaction conditions for the
reductive amination of 1,2-PPDO, reactions with lyophilized
whole cells (LWC) containing Cv-(S)TA and diﬀerent concen-
trations of the amine donor (S)-α-MBA were investigated and
applied to the reductive amination with At-(R)TA (see ESI†). A
concentration of 15 mM (S)-α-MBA was suﬃcient to achieve
full conversion of 10 mM 1,2-PPDO with Cv-(S)TA in 48 h. With
higher concentrations of the amine donor (S)-α-MBA the aceto-
phenone concentration (co-product formed upon deamination
of (S)-α-MBA) did not increase to more than 10 mM, indicating
that the theoretically possible di-amination of the diketone
1,2-PPDO did not occur. This is in accordance with previous
results in which the reductive amination of aryl-aliphatic
ketones can only be achieved if the aliphatic group is not
larger than an ethyl group.35 The initial rate activity for the
reductive amination of 1,2-PPDO towards (S)-APPO was ∼0.005
U mgLWC
−1 with LWC containing overexpressed Cv-(S)TA or
∼0.008 U mgprotein−1 with purified Cv-(S)TA (see ESI;† 1 U cor-
responds to the amount of enzyme that catalyzes the conver-
sion of 1 µmol min−1 1,2-PPDO under standard conditions). In
contrast to this, in a reaction with E. coli crude cell extract con-
taining At-(R)TA (Scheme 5 B-1) a significantly higher activity
of ∼0.1 U mgprotein−1 was measured for the synthesis of (R)-
APPO. Here, in all cases a complete conversion of the diketone
substrate was observed in only 3 h (see ESI†).
The subsequent reduction reaction of the intermediate
product APPO can in principle be performed in the same pot
without intermediate isolation. The required cofactor NADPH
(0.5 mM) was regenerated by the addition of formate dehydro-
genase (FDH) from Pseudomonas sp. and sodium formate,
based upon a method described previously.36 When the
cascade was performed in the sequential mode without
quenching the TA reaction, 1-phenylpropane-1,2-diol was
detected as a by-product. This was most likely due to the rever-
sibility of the TA reaction and an equilibrium that favoured the
di-reduction of PPDO by ADH. To suppress the diol formation,
inactivation of the TA after the first reaction step was investi-
gated. Either a pH-shift (pH 7.5 to pH 2 with 20% (v/v) HCl –
and re-titration to pH 7.5 with 1 M NaOH) or an ultrafiltration
step to remove the TA was tested. Using inactivation by pH-
shift, the combination Cv-(S)TA/LbADH as purified enzymes
gave an overall conversion of 80% after 52 h. With this biocata-
lytic cascade the product (1S,2S)-NPE was accessible for the
first time with high optical purity: de >99% and ee >98%
(Table 1; entry #4). When ultrafiltration was used to remove
the TA for the combination of Cv-(S)TA/LbADH with purified
enzymes, the 2-step conversion was significantly lower (57%
after 60 h), but ee and de remained equally high (Table 1;
entry #2 compared to #4). The same trend was found for the
combination of Cv-(S)TA/RADH with purified enzymes, where
the product (1R,2S)-NE was accessible with ee >99% and de
>95% (Table 1; entry #3). Here, the 2-step cascade with an
ultrafiltration step after the TA reaction resulted in an overall
conversion of 55%, whereas 82% conversion to (1R,2S)-NE was
achieved using the pH-shift for TA inactivation (Table 1; entry
#3 compared to #5). Possible explanations for the reduced yields
upon ultrafiltration might be that centrifugation was carried out
in plastic ware (all other steps were performed in closed glass
vials) and evaporation and adsorption of the intermediate might
lower the final yield significantly. However, this was not investi-
gated in detail because the cheaper pH-shift method solved the
problem and even higher ee- and de-values (ee 99%, de 97%).
Compared to the excellent optical purity of (1S,2S)-NPE
obtained in the 2-step reaction with purified enzymes (see
above), the biotransformations using lyophilized whole cells
yielded products with decreased optical purities (Table 1; entry
#8, 9): Cv-(S)TA/LbADH ((1S,2S)-NPE: ee >92%, de 90%) and
Cv-(S)TA/RADH ((1R,2S)-NE: ee >99%, dr ∼8 : 2). Here, a
decrease in optical purity might be caused by the isomeriza-
tion of (S)-APPO, induced by other E. coli enzymes. Although it
was not possible to measure the ee for the intermediate
product APPO, this isomerization could lead to a decrease of
the de for the N(P)E products even if both cascade enzymes
(ADH and TA) are highly selective.
Scheme 5 Strategy B: enzymatic 1-pot 2-step reaction for the syn-
thesis of all nor(pseudo)ephedrines combining either an (S)-selective
(Cv-(S)TA, strategy B-1) or an (R)-selective transaminase (At-(R)TA, strat-
egy B-2) in the ﬁrst step and an (R)- (RADH) or (S)-selective (LbADH)
alcohol dehydrogenase (ADH) in the second step.
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Similar results were obtained when a crude cell extract
containing At-(S)TA was used for the reductive amination
step. In combination with RADH (purified enzyme) high con-
versions (>90%) but rather low optical purities ((1R,2R)-
NPE: ee >99%, de >55%) were detected (Table 1; entry #7).
Moreover, the combination At-(R)TA/LbADH did not result in
(1S,2R)-NE as the major product, but gave (1S,2S)-NPE
(Table 1; entry #6, 10). As mentioned for the cascades with
Cv-(S)TA lyophilized whole cells, an isomerization of APPO
could lead to a decrease in de values even if the enzymes
applied are highly selective.
As a consequence, purified enzymes rather than whole cells
or crude cell extracts are the method of choice for the TA/ADH
reaction cascade. As shown for the combination Cv-(S)TA/
LbADH, (1S,2S)-NPE is accessible in high optical purities
(>99% de, >98% ee) when purified enzymes are used in both
reaction steps (Table 1; entry #4).
Conclusions
In summary, two biocatalytic cascade strategies have been
developed for the synthesis of all four phenylpropanolamine
stereoisomers and the use of inexpensive whole cells for the
reaction steps has been investigated. In the “carboligase-TA”
strategy, a combination of the (R)-selective AHAS-I from E. coli
either with an (S)- or a (R)-selective ω-TA gave access to (1R,2S)-
NE and (1R,2R)-NPE in high optical purities (ee >99% and de
>98%). As a proof-of-principle we demonstrated that the syn-
thesis of (1R,2R)-NPE could be performed with substrate con-
centrations of up to 100 mM by the combination AHAS-I/At-(R)
TA. Space–time yields up to ∼26 g L−1 d−1 were achievable.
Moreover, the application of LWC is possible, but leads to a
reduction in specific STY by a factor of 10 for the C–C coupling
reactions and by a factor of 5 for the reductive transami-
nations. Since a highly (S)-selective enzyme for the synthesis of
the intermediate (S)-PAC is currently not available, the pro-
ducts (1S,2R)-NE and (1S,2S)-NPE were only accessible in mod-
erate optical purities using this strategy.
An alternative 2-step synthesis strategy combining ω-TA
with ADHs was evaluated to gain access to all N(P)E isomers in
higher optical purities. Indeed, the isomer (1S,2S)-NPE, also
known as cathine, was synthesized enzymatically in high
optical purities. Here, the combination of the (S)-selective TA
Cv-(S)TA with the (S)-selective alcohol dehydrogenase LbADH
gave (1S,2S)-NPE with an ee >98% and a de >99% when puri-
fied enzymes were used. This novel biocatalytic reaction
cascade can be performed in one pot without isolation of
intermediates. However, a deactivation of the ω-TA prior to the
reductive hydrogenation was required. Although it was demon-
strated that this reaction could be carried out with cheaply pro-
duced lyophilized whole cells, there are two major drawbacks.
On the one hand, the specific STYs are significantly lower with
lyophilized whole cells, which partially negate the 10-fold
lower catalyst production costs of cells. On the other hand, the
optical purity of the product was higher with purifiedTa
b
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enzymes. Since chiral product purification methods might dra-
matically increase production costs, the use of purified
enzymes can be beneficial if the additional enzyme purifi-
cation costs are below downstream processing costs. For indus-
trial applications immobilization of enzymes might be a
method to decrease production costs (e.g. in terms of down-
stream processing, recyclability) and in some cases immobili-
zation results in an increased catalyst stability and/or
activity.37–42
In general, it has been demonstrated that enzymes from
diﬀerent toolboxes can be eﬃciently combined yielding all
stereoisomers of desired N(P)E. Here, the “TA-ADH” reaction
cascade was developed as an alternative to the “carboligase-
TA” cascade giving access to optically pure (1S,2S)-NPE in only
two biocatalytic steps.
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